Here are the top 5 biosimilar articles for the week of August 31, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of August 31, 2020.
Number 5: British Columbia's Pharmacare prescription coverage plan entered into its third phase of the program this month, where enrolled residents who are receiving reference rituximab will be switched to 1 of 3 biosimilar versions.
Number 4: Lupin Limited and Mylan have launched the biosimilar etanercept Nepexto in Germany for the treatment of several inflammatory diseases.
Number 3: Biocon Biologics and Mylan said they have launched the long-acting insulin glargine product Semglee on the US market and hope to obtain formal biosimilar status for it.
Number 2: Continuing with its string of recent biosimilar launches, Cadila Pharmaceuticals has put an adalimumab biosimilar (Cadalimab) on the Indian market.
Number 1: As the global pandemic cases topped 25 million by late summer 2020, many biosimilar manufacturers had joined the fight to find treatments for coronavirus disease 2019 (COVID-19).
To read all of these articles and more, visit centerforbiosimilars.com.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.